Lyra Therapeutics, Inc. (the Company or Lyra) announced the appointment of John Bishop, Ph.D., as Chief Technology Officer, effective February 27, 2023. Dr. Bishop will lead the commercial scale-up of Lyra's manufacturing operations for the Company's late-stage product candidates, LYR-210 and LYR-220.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3676 USD | +3.32% | -4.89% | -92.98% |
07/05 | Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 | MT |
07/05 | HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-92.98% | 22.41M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.28% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- LYRA Stock
- News Lyra Therapeutics, Inc.
- Lyra Therapeutics, Inc. Announces Appointment of John Bishop as Chief Technology Officer